

# Eric Tansky

## Eric Tansky

Managing Director

- Eric leads Wedbush's Med Tech franchise and has executed 45 M&A and financing transactions with aggregate value of over \$60 billion. Eric's range of strategic transaction experience includes sell-side and buy-side M&A advisory, attempted hostile take-over and defense advisory assignments. Eric's financing experience includes both public and private equity, debt, and convertible issuance. Eric has worked on a number of marquee sector
- Prior to joining Wedbush Eric spent the majority of his career in the healthcare groups of Credit Suisse and Merrill Lynch
- Spent several years as an Orthopedic sales consultant and a submarine officer and U.S. Navy Diver
- BS in Weapons System Engineering from the U.S. Naval Academy noted as a Distinguished Graduate and winner of the Brainard Award, MBA from Columbia Business School

## Selected M&A Experience

- Sale of Devicor to Danaher (terms not disclosed)
- Sale of CircuLite to Heartware \$350 million
- Sale of KCI Beds to Getinge \$270 million
- Sale of LMA to Teleflex \$275 million
- Agilent's acquisition of DAKO A/S \$2.1 billion
- Sale of Sythes to J&J \$22.3 billion
- Sale of Cellestis to Qiagen \$395 million
- Sale of Celera to Quest \$650 million
- Getinge's acquisition of Datascope \$865 million
- Tomotherapy defense advisory
- Hologic's acquisition of Suros \$260 million

## Selected Financing Experience

- Valeritas \$52 million follow-on and \$25 million PIPE
- RECRO Pharma \$30 million PIPE
- Quotient Limited \$30 million PIPE
- ReWalk's \$40 million IPO
- Wright Medical block trades
- Heartware follow-on \$130 million
- Apax's \$5.0B debt financing to acquire KCI
- Tornier IPO \$165 million
- AOBO convertible offering \$110 million
- AthenaHealth IPO \$130 million
- Lincare convertible offering \$550 million
- TomoTherapy IPO \$255 million and follow-on \$220 million